SCR7 pyrazine |
| Catalog No.GC14335 |
La pirazina SCR7 es un inhibidor de la ADN ligasa IV que bloquea la uniÓn de extremos no homÓlogos (NHEJ) de una manera dependiente de la ligasa IV. La pirazina SCR7 también es un potenciador de CRISPR/Cas9 que aumenta la eficiencia de la reparaciÓn dirigida por homologÍa (HDR) mediada por Cas9. La pirazina SCR7 induce la apoptosis celular y tiene actividad anticancerÍgena.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 14892-97-8
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
SCR7 pyrazine is an inhibitor of DNA ligase IV [1].
DNA Ligase IV is involved in sealing of double-strand breaks (DSBs) during nonhomologous end-joining (NHEJ). DSBs have been considered as one of the most lethal types of DNA damage within cells. Unrepaired DSBs may lead to chromosomal rearrangements such as translocations and deletions, resulting in oncogenic transformations or cell death. In higher eukaryotes, NHEJ is one of the primary mechanisms of DSB repair and is active throughout the cell cycle. NHEJ plays a major role in providing resistance to cancer cells to these radio- and chemotherapy agents [1].
SCR7 blocked Ligase IV-mediated joining by interfering with its DNA binding in cell-free repair system. SCR7 inhibited NHEJ in a Ligase IV-dependent manner within cells, and activated the intrinsic apoptotic pathway. SCR7 dose-dependent decreased cell proliferation in MCF7, A549, and HeLa cells with an IC50 of 40, 34, and 44 μM, respectively. In T47D, A2780, and HT1080 cells, the IC50 values were 8.5, 120, and 10 μM, respectively [1].
SCR7 treatment (10 mg/kg, six doses) significantly reduced breast adenocarcinoma-induced tumor and impeded tumor progression in mouse models in mouse models. Coadministered of SCR7 with DSB-inducing therapeutic modalities significantly enhanced their sensitivity.
Reference:
[1] Srivastava M, Nambiar M, Sharma S, et al. An inhibitor of nonhomologous end-joining abrogates double-strand break repair and impedes cancer progression[J]. Cell, 2012, 151(7): 1474-1487.
| Cas No. | 14892-97-8 | SDF | |
| Chemical Name | 2,3-dihydro-6,7-diphenyl-2-thioxo-4(1H)-pteridinone | ||
| Canonical SMILES | O=C(C1=NC(C2=CC=CC=C2)=C(C3=CC=CC=C3)NC1=N4)NC4=S | ||
| Formula | C18H12N4OS | M.Wt | 332.4 |
| Solubility | ≥ 33.2mg/mL in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.0084 mL | 15.0421 mL | 30.0842 mL |
| 5 mM | 0.6017 mL | 3.0084 mL | 6.0168 mL |
| 10 mM | 0.3008 mL | 1.5042 mL | 3.0084 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 6 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *